

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1-63. (Cancelled)

64. (Previously amended) A method for identifying an antagonist of an opioid receptor like 1 (ORL₁) comprising:

(a) contacting an ORL₁ receptor with a polypeptide comprising the sequence of SEQ ID NO: 2 in the presence of a candidate modulator under conditions which permit binding of said polypeptide to said ORL₁ receptor; and

(b) measuring production of a second messenger wherein a change in the concentration of a second messenger measured in the presence of said candidate modulator relative to the concentration of said second messenger in the absence of said candidate modulator identifies said candidate modulator as an antagonist of said ORL₁ receptor.

65. (Previously presented) The method of claim 64, wherein said second messenger is cAMP.

66. (Previously presented) A method of identifying an agent that binds to an opioid receptor-like 1 (ORL₁) receptor, said method comprising:

(a) contacting an ORL₁ receptor with an isolated peptide comprising the sequence of SEQ ID NO: 2 in the presence or absence of said agent under conditions permitting the binding of said isolated peptide to said ORL₁ receptor; and

(b) measuring the binding of said ORL₁ receptor to said isolated peptide, wherein a decrease in binding in the presence of said agent, relative to the binding in the absence of said agent identifies said agent as an agent that binds to said ORL₁ receptor.

67. (New) The method of claim 64 or 66, wherein said ORL₁ receptor is present in or on a cell.

68. (New) The method of claim 64 or 66, wherein said ORL₁ receptor is present in a membrane fraction from cells which express said ORL₁ receptor.